Next-Generation Therapeutic Strategies for Relapsed/Refractory Multiple Myeloma: Targeting BCMA

Download All
Experts discuss how they incorporate BCMA-targeted agents into the treatment of patients with MM and manage toxicities associated with these agents. This program features ClinicalThought commentaries, downloadable slides, and an on-demand webcast from a live webinar.
Sagar Lonial, MD
Program Director
Suzanne Lentzsch, MD, PhD
Thomas G. Martin, MD

On-Demand Webcast

On-demand webcast of a CCO live webinar on the use of BCMA-targeted agents in relapsed/refractory multiple myeloma.

Sagar Lonial, MD
Program Director
Suzanne Lentzsch, MD, PhD Thomas G. Martin, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: October 15, 2021 Expired: October 14, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
GlaxoSmithKline
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings